Grand Mal Seizure Market

On 17 September 2025, SK Biopharmaceuticals announced Phase 3 results showing that cenobamate, sold in the United States as Xcopri, cut the frequency of primary generalized tonic-clonic seizures by 71.9% from baseline, against 39.6% for placebo, and said it would seek to add the indication to a drug approved until then only for focal seizures. Xcopri had just posted record US sales of USD 111 million in a single quarter, and a label for grand mal seizures would put one of the fastest-growing branded antiseizure medicines into the seizure type that carries the highest risk of injury and sudden death in epilepsy. Douglas Insights values the grand mal seizure market at USD 4.92 billion in 2025 and forecasts USD 8.30 billion by 2035, a compound growth rate of 5.37%. The receipt is about 16.5 million people treated for generalized tonic-clonic seizures worldwide in 2025 at an average realised drug spend of USD 298 per patient a year. Treated patients grow 2.3% a year as diagnosis and treatment reach more people in Asia, Latin America and Africa; spend per patient grows 3.0% a year as newer branded medicines and rescue therapies take a larger share of care. The report sits within Douglas Insights coverage of pharmaceuticals and follows the published Douglas Insights research methodology.

What does the grand mal seizure market include?

The grand mal seizure market covers medicines used to prevent, stop and manage generalized tonic-clonic seizures, worth USD 4.92 billion in 2025 across about 16.5 million treated patients. A grand mal, or tonic-clonic, seizure involves loss of consciousness, stiffening of the body and rhythmic jerking of the limbs, and it can start in both halves of the brain at once, called primary generalized, or spread from one area, called focal to bilateral. The market includes daily maintenance antiseizure medicines taken to prevent seizures, both generic and branded; rescue medicines such as nasal, buccal and rectal benzodiazepines that carers give during a prolonged seizure or a cluster; hospital medicines used to stop status epilepticus, a seizure that does not end on its own; and other therapies used in severe childhood epilepsies where tonic-clonic seizures are common. Spending is attributed to tonic-clonic seizures by the share of each medicine’s use in patients who have them. Surgery, vagus nerve and deep brain stimulation devices, diagnostic tests, seizure-detection wearables and medicines for absence or purely focal seizures are outside the boundary. Douglas Insights estimates that about 60% of people with epilepsy have tonic-clonic seizures at some point, which is why the grand mal seizure market accounts for roughly half of all antiseizure medicine spending worldwide.

What does the cenobamate trial mean for the grand mal seizure market?

The cenobamate result reported on 17 September 2025 could add about USD 150 million a year to branded grand mal seizure spending by 2030, on Douglas Insights estimates, if regulators approve the new use. The trial tested cenobamate added to existing treatment in people whose primary generalized tonic-clonic seizures were not controlled, and the 71.9% reduction compares with results that won approval for earlier medicines in the same setting. That matters because the choice of branded medicines approved specifically for primary generalized tonic-clonic seizures is short: perampanel, lacosamide, levetiracetam, lamotrigine and topiramate carry the indication in the United States, and most are now generic. Uncontrolled tonic-clonic seizures are the main risk factor for sudden unexpected death in epilepsy, so neurologists move quickly to add a new medicine when one fails, and a drug with strong data in this seizure type can take share fast. SK’s result also shows how the market is changing: growth now comes from medicines that work across seizure types, from rescue therapies used at home, and from reaching patients in low- and middle-income countries who today receive no treatment at all, rather than from price rises on old generics.

What drives grand mal seizure treatment demand?

Grand mal seizure treatment demand is driven by four forces, and Douglas Insights attributes 2.3 points of the 5.37% annual growth to more patients treated and 3.0 points to higher spend per patient.

Closing the treatment gap is the largest source of new patients. The World Health Organization estimates that about 50 million people have epilepsy, that nearly 80% live in low- and middle-income countries, and that up to 70% could live seizure-free with proper diagnosis and treatment, yet in low-income countries about three-quarters of people with epilepsy go untreated. Douglas Insights estimates Asia Pacific at USD 1.14 billion in 2025, growing 6.9% a year as China and India expand neurology services.

Newer branded maintenance medicines raise spend per patient. Drugs such as perampanel, lacosamide, brivaracetam and cenobamate cost far more than first-generation medicines, and they are used when two older drugs have failed, which happens in about a third of patients. Douglas Insights estimates branded maintenance medicines at USD 1.48 billion in 2025, 30% of value, growing 8.0% a year.

Rescue therapy moves care from the emergency room to home. Nasal diazepam, nasal midazolam and buccal diazepam film let a carer stop a seizure cluster or a prolonged seizure without an ambulance, and prescriptions have grown quickly in the United States since the first nasal products were approved. In April 2024 the US Food and Drug Administration approved Aquestive’s Libervant diazepam buccal film for children aged two to five, widening home rescue to the youngest patients. Douglas Insights estimates rescue therapies at USD 689 million in 2025, growing 9.5% a year, the fastest of any segment.

Older and larger populations add patients. Epilepsy is most common in young children and in people over 65, where stroke, dementia and brain tumours cause new seizures, so ageing populations in Europe, Japan and China add treated patients every year. The Health Self Monitoring Technologies Market report covers the wearable devices that now alert carers when a tonic-clonic seizure starts.

Specialist childhood epilepsies add a smaller stream. Syndromes such as Dravet and Lennox-Gastaut cause frequent tonic-clonic seizures, and approved medicines for them cost tens of thousands of dollars a year, so Douglas Insights estimates paediatric patients at 22% of value, USD 1.08 billion, well above their share of patient numbers.

What restraints hold back the grand mal seizure market?

Generic prices, the treatment gap and side effects hold back the grand mal seizure market, and Douglas Insights estimates they take about 1.5 points a year off value growth. Most patients take generic levetiracetam, valproate, lamotrigine or carbamazepine, which cost a few dollars a month in many countries, and every branded medicine eventually loses exclusivity, as lacosamide did in the United States in 2022. The treatment gap works in both directions: it is the largest pool of future patients, but closing it depends on neurologists, EEG machines and reliable drug supply in health systems that lack all three, and progress is slow. Side effects limit use of some medicines: valproate carries serious risks in pregnancy, which has led European regulators to restrict its use in girls and women of childbearing potential, and several newer drugs need slow dose increases or cause dizziness and mood changes. Finally, about a third of patients do not become seizure-free with any medicine, and some of them move to surgery or neurostimulation, which sit outside this market.

Which grand mal seizure segment carries the most value?

Generic maintenance medicines are the largest grand mal seizure segment at 42% of 2025 value, USD 2.07 billion, and rescue therapies are the fastest-growing segment at 9.5% a year.

Generic maintenance medicines are worth USD 2.07 billion in 2025. Levetiracetam, valproate, lamotrigine, topiramate, carbamazepine and phenytoin treat most patients worldwide, and volume growth in Asia and Africa offsets price erosion, giving 2.8% annual growth.

Branded maintenance medicines are worth USD 1.48 billion in 2025. Perampanel, brivaracetam, cenobamate and other newer medicines are used after older drugs fail, giving 8.0% annual growth.

Rescue therapies are worth USD 689 million in 2025. Nasal and buccal benzodiazepines prescribed for home use give 9.5% annual growth, the fastest.

Hospital and status epilepticus medicines are worth USD 492 million in 2025. Intravenous benzodiazepines, levetiracetam, fosphenytoin and anaesthetic agents used in emergency departments and intensive care grow 4.0% a year.

Other therapies, including medicines for severe childhood epilepsy syndromes, are worth USD 197 million in 2025 and grow 6.0% a year.

By patient group, adults take 78% of value, USD 3.84 billion, and children 22%, USD 1.08 billion. By channel, retail pharmacies take 62%, USD 3.05 billion; hospitals 26%, USD 1.28 billion; and specialty and online pharmacies 12%, USD 590 million.

How do maintenance and rescue grand mal seizure treatments differ?

Maintenance medicines take about 72% of grand mal seizure spending in 2025, while rescue therapies take 14%, but rescue therapy is growing more than three times as fast as generic maintenance treatment, on Douglas Insights estimates. Maintenance medicines are taken every day, often for life, to reduce how often seizures happen; the choice depends on seizure type, age, sex, other conditions and side effects, and many patients need two or three medicines together. Rescue medicines are used only when a seizure lasts longer than usual or several come close together, and their value lies in stopping the seizure before it becomes status epilepticus, which needs hospital care and carries a real risk of death. Nasal sprays and buccal films replaced rectal gels because they are easier and more dignified for carers to use in public, at school or at work. A patient on a generic maintenance drug may spend under USD 100 a year on it in many countries, while a family using a branded nasal rescue product in the United States can spend several hundred dollars on each two-dose pack. Douglas Insights expects rescue prescribing to spread from the United States to Europe and Japan as more products gain approval there. Schools and care homes are part of the shift: written seizure action plans increasingly name a rescue medicine and who may give it, which turns a one-off prescription into a repeat purchase as packs expire or are used.

Where is grand mal seizure treatment bought, and which region grows fastest?

North America buys the most grand mal seizure treatment, 44% of 2025 value or USD 2.18 billion, while Africa is the fastest-growing region at 8.2% a year from a small base. North America leads because branded medicines and rescue therapies are widely prescribed and priced far above other markets; it grows 5.1% a year as cenobamate and other newer medicines gain use. Asia Pacific, at USD 1.14 billion, treats the most patients by far, led by China, India and Japan, and grows 6.9% a year as diagnosis improves. Europe is worth USD 1.04 billion and grows 3.3% a year, held back by lower prices and generic substitution. Latin America, at USD 300 million, grows 6.1% a year as Brazil and Mexico widen access to newer medicines. The Middle East, at USD 170 million, is the wildcard: Gulf health systems adding branded medicines to their formularies could lift growth above the 6.5% base case. Africa, at USD 90.0 million, grows 8.2% a year as epilepsy programmes supported by the World Health Organization bring treatment to rural areas.

Who makes grand mal seizure medicines?

UCB leads the grand mal seizure market with an estimated 18% of 2025 value, and generic manufacturers together supply about 30%, on Douglas Insights estimates.

UCB’s position rests on a family of medicines built around levetiracetam and its successor brivaracetam, lacosamide, and the nasal midazolam rescue spray, which together cover maintenance and rescue. Sanofi and GSK still earn from original brands in markets where patients and doctors prefer them. SK Biopharmaceuticals has built the fastest-growing new brand, and the tonic-clonic result could widen its use. Neurelis leads US nasal rescue therapy, and Catalyst took over US rights to perampanel from Eisai in 2023. Generic manufacturers compete on price and supply reliability, and shortages of older medicines such as phenytoin and carbamazepine in some countries show how thin that supply can be. Douglas Insights expects further consolidation as larger companies buy late-stage epilepsy medicines, because the market rewards broad labels and long patient persistence.

How are grand mal seizure medicines priced?

Annual grand mal seizure drug costs range from under USD 50 for generic phenobarbital or carbamazepine in low-income countries to more than USD 15,000 for branded maintenance medicines in the United States, and the Douglas Insights average is USD 298 per treated patient in 2025. Generic levetiracetam and lamotrigine cost about USD 50 to 300 a year in most markets. Branded newer medicines such as cenobamate and brivaracetam list at about USD 12,000 to 17,000 a year in the United States and about a fifth to a third of that in Europe and Japan. Nasal rescue products cost several hundred dollars per two-dose pack in the United States. Hospital treatment of status epilepticus adds drug costs of a few hundred to a few thousand dollars per episode. In India and much of Africa, public programmes buy generic medicines by tender at a few cents per tablet, which is why Asia Pacific treats the most patients but earns less than North America. Spend per patient grows about 3.0% a year from the shift to newer medicines and rescue therapy, partly offset by generic entry.

How could the grand mal seizure forecast change by 2035?

The grand mal seizure forecast ranges from about USD 6.43 billion to USD 10.8 billion in 2035 across Douglas Insights scenarios, around a base case of USD 8.30 billion. The slower case assumes patient growth of 1.2% a year and spend growth of 1.5%, which would follow if the treatment gap in low-income countries closes slowly and generic entry erodes branded prices faster. The faster case assumes 3.4% and 4.6%, which would follow if cenobamate and other pipeline medicines win tonic-clonic labels and rescue therapy spreads to Europe and Asia. The pipeline matters most for the faster case: Xenon Pharmaceuticals is testing azetukalner, a potassium channel opener, in a Phase 3 trial in primary generalized tonic-clonic seizures, and UCB is developing Staccato alprazolam, an inhaled rescue therapy designed to stop a seizure within minutes. Each 1-point change in patient growth moves the 2035 figure by about USD 848 million. Published forecasts for tonic-clonic and epilepsy drug markets sit between about 4.6% and 6.5% a year, and Douglas Insights’ 5.37% sits in the middle of that range.

Douglas Exclusive: grand mal seizure treatment gap tracker

The Douglas Insights grand mal seizure treatment gap tracker estimates, for 60 countries, how many people have tonic-clonic seizures, how many are diagnosed, how many receive any antiseizure medicine and how many reach newer or rescue treatment. It shows that about 16.5 million people with tonic-clonic seizures received treatment in 2025, that at least 10 million more did not, and that closing half of that gap by 2035 would add about USD 400 million a year to the market at today’s prices in the regions concerned.

Which regulations and standards shape the grand mal seizure market?

Drug approval rules and safety restrictions shape the grand mal seizure market, and Douglas Insights estimates that about 35% of 2025 value comes from medicines with a specific tonic-clonic or rescue indication. In the United States, the Food and Drug Administration approves antiseizure medicines by seizure type, so a medicine approved for focal seizures needs new trials, such as the cenobamate study, to be promoted for primary generalized tonic-clonic seizures. Rescue products are approved for seizure clusters, and several benzodiazepines are controlled substances, which limits how much can be dispensed. In Europe, the European Medicines Agency restricted valproate in 2018 through a pregnancy prevention programme and extended precautions in 2024, which shifts prescribing to other medicines for girls and women. The World Health Organization’s Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders, adopted in 2022, commits countries to widen access to essential antiseizure medicines, which supports patient growth in low- and middle-income countries.

What methodology sits behind the grand mal seizure market model?

The grand mal seizure market model is a bottom-up count across 60 countries: Douglas Insights multiplied about 16.5 million people treated for tonic-clonic seizures in 2025 by an average realised drug spend of USD 298 per patient to reach USD 4.92 billion. Patient numbers were built from epilepsy prevalence, the share of patients with tonic-clonic seizures and national treatment rates, and spend from prescription data, list and net prices and the share of each medicine’s use in tonic-clonic seizures, checked against company revenue for leading brands. Shares for leading companies are Douglas Insights estimates. The Zebrafish Market report covers the fish models widely used to screen new antiseizure compounds, and the Intraoperative Neuromonitoring Systems Market report covers monitoring in epilepsy surgery. Full receipts are in the Douglas Insights research methodology.

Sources

1. Fierce Pharma SK's Xcopri reduces seizures in phase 3 trial, teeing up FDA expansion bid (17 September 2025) (2025)
2. World Health Organization Epilepsy fact sheet (2026)